Takeda Pharmaceutical Company Limited (TAK)
| Previous close | 14.02 |
| Open | 14.10 |
| Bid | 14.05 x 900 |
| Ask | 14.06 x 1400 |
| Day's range | 14.05 - 14.11 |
| 52-week range | 13.19 - 17.15 |
| Volume | |
| Avg. volume | 1,875,493 |
| Market cap | 44.197B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 34.30 |
| EPS (TTM) | 0.41 |
| Earnings date | N/A |
| Forward dividend & yield | 0.66 (4.23%) |
| Ex-dividend date | 29 Sept 2022 |
| 1y target est | 17.52 |
Business WireTakeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
OSAKA, Japan & CAMBRIDGE, Mass., November 27, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego. Takeda’s latest research focuses on improving treatment options for those living with hematologic diseases.
ZacksAre Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Reuters
UPDATE 2-Takeda Pharma gets US FDA approval for rare blood disorder therapy
The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients. Takeda's Adzynma becomes the first treatment available to patients with congenital thrombotic thrombocytopenic purpura (TTP). Congenital TTP is a life-threatening, rare genetic disorder with debilitating chronic symptoms.
